阿帕替尼对肝癌细胞增殖和迁移能力的影响研究  

Effect of apatinib on the proliferation and migration of liver cancer cells

作　　者：姜增凯[1] 叶晓歌[1] 陈琴华 

机构地区：[1]南阳市第二人民医院药学部,河南南阳473000 [2]武汉市人民医院药剂科,武汉415000

出　　处：《中国临床药理学杂志》2016年第15期1422-1424,共3页The Chinese Journal of Clinical Pharmacology

基　　金：湖北省教育厅科研计划基金资助项目(B20092410)

摘　　要：目的研究阿帕替尼对人肝癌Hep G2细胞增殖和迁移能力的影响。方法将人肝癌Hep G2细胞对数生长期的细胞分成对照组和实验组。对照组不予任何处理,实验组分别给予0.01,0.05,0.1,0.5,1.0,5.0,10.0,20.0μmol·L^(^(-1))的阿帕替尼处理,并测定细胞生长抑制率、移行愈合率,测定细胞内P53、caspase-3和caspase-8的表达情况。结果实验组细胞生长抑制率分别为(17.11±0.83)%,(27.54±1.02)%,(33.84±0.92)%,(37.43±1.13)%,(41.29±1.87)%,(46.68±1.36)%,(53.42±2.03)%,(70.44±2.58)%,随着药物浓度增加而增强。0.05,0.1μmol·L^(-1)的阿帕替尼移行愈合率分别为(45.50±4.30)%和(37.50±3.43)%,与对照组的(84.60±6.88)%比较,差异有统计学意义(P<0.01)。2.1μmol·L^(-1)阿帕替尼组P53为(112.31±6.53)%,caspase-3为(137.93±10.01)%,caspase-8为(104.63±3.89)%,4.2μmol·L^(-1)阿帕替尼组P53为(147.69±9.67)%,caspase-3为(306.89±20.15)%,caspase-8(139.09±8.82)%(P<0.01)。结论阿帕替尼可以抑制人Hep G2肝癌细胞后肿瘤细胞的生长和迁移愈合,其机制可能是上调了P53、caspase-3和caspase-8的表达。Objective To evaluate the effect of apatinib on human hepatoma cell line HepG2 post - tumor cell markers in order to provide reference for medicine treatment of liver cancer. Methods HepG2 human hepatoma ceils in logarithmic growth phase were divided into control group and test group. Control group was given no special treatment, test group was given 0.01, 0.05, 0.1, 0.5, 1.0, 5.0, 10.0, 20.0 μ mol · L^-1 apatinib. The cell growth inhibition rate, transitional healing rate, and the expressions of P53, caspase - 3, and caspase - 8 in cells were determined. Results The inhibition rates of test group were （17.11 ± 0.83）%, （27.54 ± 1.02）%, （33.84 ± 0.92）%, （37.43 ±1.13）% ,（41.29 ± 1.87）%, （46.68 ± 1.36）%, （53.42 ±2.03 ） % , （70.44 ± 2. 58 ） % , enhanced with the increase of drug concentration. The contrast transitional healing rate of 0.05, 0. 1 μmol · L^-1 test groups were （45.50 ± 4. 30 ） %, （ 37.50 ± 3.43 ） %, with significant difference with control group, which was （84. 60 ± 6. 88 ）% （P 〈 0. 01 ）. The expressions of P53, caspase -3, and caspase -8 in 2.1 μmol· L^-1 apatinib group were （112.31 ± 6.53）%, （137.93±10.01）% ,（104. 63 ±3.89）%, and were （147.69 ±9.67）%, （306. 89 ± 20. 15 ） %, （ 139. 09 ± 8. 82 ） % in 4. 2 μmol· L^-1 apatinib group（P 〈0. 01 ）. Conclusion Apatinib could inhibit the growth and migratory healing of human HepG2 hepatoma cells, its mechanism might be correlated with the upregulated expressions of P53, caspase -3 and caspase -8.

关 键 词：肝癌细胞系Hep G2 阿帕替尼 抑制作用 

分 类 号：R979.1[医药卫生—药品]